HEPATOBILITY

DNA adducts, detected by ³²P postlabelling, in human cholangiocarcinoma

S A Khan¹, P L Carmichael², S D Taylor-Robinson¹, N Habib³, H C Thomas¹

¹ The Liver Centre, Division of Medicine A, Faculty of Medicine, Imperial College London, St Mary’s Hospital Campus, South Wharf St, London W2 1PG, UK
² Section of Biological Chemistry, Faculty of Medicine, Imperial College London, South Kensington Campus, Exhibition Rd, London SW7 2AZ, UK
³ Department of Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12, UK

Correspondence to:
Correspondence to:
Dr S A Khan, Liver Unit, Department of Medicine A, 10th Floor, QEQM Wing, Faculty of Medicine, Imperial College London, St Mary’s Hospital, South Wharf St, London W2 1NY, UK;
shahid.khan{at}ic.ac.uk

Background: Reported mortality from intrahepatic cholangiocarcinoma (CCa) has risen steeply in the UK and other industrialised countries over the past 30 years, the cause of which has not been explained. DNA adduct formation is promutagenic and demonstrates exposure to a DNA damaging agent. It is a key step in chemically induced carcinogenesis. We hypothesise that the increase in CCa mortality is caused by a rise in a genotoxic environmental agent(s), causing cholangiocyte DNA damage.

Aims: To investigate and compare tumour and tumour adjacent CCa tissue, and non-cancer control bile duct tissue, for DNA adducts as a biomarker of genotoxin exposure.

Methods: DNA from 32 intrahepatic CCa patients (and in 28 cases DNA from adjacent non-tumour tissue) and from biliary ducts of seven non-cancer patients were investigated for the presence of DNA adducts using the nuclease P1 method of ³²P postlabelling. DNA adduct levels (number of adducts/10⁸ nucleotides) were quantified.

Results: There was no significant difference in relative adduct labellings (RALs) between tumour adjacent DNA (median 8.6, range 1.2–51.6) and CCa DNA (7.2, 1.8–48.4). However, RALs were significantly higher in DNA from cancer patients (tumour adjacent and CCa DNA) compared with non-cancer patient DNA (2.9, 0.6–11.5; p=0.032, two tailed Mann-Whitney U test). Different adduct patterns were also seen in CCa compared with non-cancer patients.

Conclusion: Quantitative and qualitative differences in adducts between cancer and non-cancer patients support the hypothesis that genotoxins may play a role in the development of intrahepatic CCa.

Keywords: cholangiocarcinoma; DNA adducts; ³²P postlabelling

Abbreviations: CCa, cholangiocarcinoma; CYP, cytochrome P450; RAL, relative adduct labelling; TLC, thin layer chromatography

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Ian Forgacs
Gut 2003 52: 459. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Gyorffy, E., Anna, L., Gyori, Z., Segesdi, J., Minarovits, J., Soltesz, I., Kostic, S., Csekeo, A., Poirier, M. C., Schoket, B. (2004). DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay. Carcinogenesis 25: 1201-1209 [Abstract] [Full Text]  
• (2003). Toxins are linked to cancer of the bile duct. Mol. Pathol. 56: 317-317 [Full Text]